Share
12,379 Posts.
lightbulb Created with Sketch. 764
clock Created with Sketch.
14/06/24
13:18
Share
Originally posted by zipperlip:
↑
The dramatic reduction in severity from the Alpha variant (which was the equivalent of a bad cold/flu) to the equivalent of a medium to mild cold/flu was always going to happen. Sure there was a possibility that the Rona may punch out a more aggressive strain at some point but the same thing could happen with any of the cold/flu viruses. The idea that we wouldn’t be able to build natural immunity was an outright Furphy. As for the reduction in severity and transmission? It is obvious that these treatments did diddly squat to reduce transmission, ask the next 100 people you meet if they’ve had a dose of the Rona and you would be lucky to find a handful who say they haven’t had it at least once. As for the “Numbers” of deaths, funny how many countries have rejiggered their official numbers and switched around the dying with and dying from statics. Then you should check out the increase in overall mortality rates in countries and match it up to the heavily/lightly compliant countries. By the way, investing in a biotech company doesn’t impress me much as an example of how you are across this issue.
Expand
I am quite disappointed in you. For starters this is not a normal flu or cold result >https://th.bing.com/th/id/OIP.B-zZQhb8t6j5QFM8X0nIYgHaFk?rs=1&pid=ImgDetMain and that did not persist as I said but it did cause the initial govt responses which you guys are complaining about BUT pointing out to what was happening AFTER the severity declined rapidly. What Biota did should be understood by anyone that invested there. Not my job to educate closed minds any further.